419 related articles for article (PubMed ID: 32699909)
1. Effect of neoadjuvant chemotherapy on health-related quality of life in patients with muscle-invasive bladder cancer: results from JCOG0209, a randomized phase III study.
Kitamura H; Hinotsu S; Tsukamoto T; Shibata T; Mizusawa J; Kobayashi T; Miyake M; Nishiyama N; Kojima T; Nishiyama H;
Jpn J Clin Oncol; 2020 Dec; 50(12):1464-1469. PubMed ID: 32699909
[TBL] [Abstract][Full Text] [Related]
2. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209.
Kitamura H; Tsukamoto T; Shibata T; Masumori N; Fujimoto H; Hirao Y; Fujimoto K; Kitamura Y; Tomita Y; Tobisu K; Niwakawa M; Naito S; Eto M; Kakehi Y;
Ann Oncol; 2014 Jun; 25(6):1192-8. PubMed ID: 24669010
[TBL] [Abstract][Full Text] [Related]
3. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD
Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698
[TBL] [Abstract][Full Text] [Related]
4. Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733.
Higano CS; Tangen CM; Sakr WA; Faulkner J; Rivkin SE; Meyers FJ; Hussain M; Baker LH; Russell KJ; Crawford ED;
Cancer; 2008 May; 112(10):2181-7. PubMed ID: 18404692
[TBL] [Abstract][Full Text] [Related]
5. Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion.
Metcalfe MJ; Ferguson JE; Li R; Xiao L; Guo CC; Czerniak BA; Siefker-Radtke A; Pretzsch SM; Navai N; McConkey DJ; Kamat AM; Campbell M; Dinney C
Eur Urol Focus; 2017 Dec; 3(6):577-583. PubMed ID: 28753816
[TBL] [Abstract][Full Text] [Related]
6. Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?
Pouessel D; Chevret S; Rolland F; Gravis G; Geoffrois L; Roubaud G; Terrisse S; Boyle H; Chevreau C; Dauba J; Moriceau G; Alexandre I; Deplanque G; Chapelle A; Vauleon E; Colau A; Audenet F; Grellety T; Culine S
Eur J Cancer; 2016 Feb; 54():69-74. PubMed ID: 26724422
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.
Grossman HB; Natale RB; Tangen CM; Speights VO; Vogelzang NJ; Trump DL; deVere White RW; Sarosdy MF; Wood DP; Raghavan D; Crawford ED
N Engl J Med; 2003 Aug; 349(9):859-66. PubMed ID: 12944571
[TBL] [Abstract][Full Text] [Related]
8. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.
; ; ; ; ; ; ; ; Griffiths G; Hall R; Sylvester R; Raghavan D; Parmar MK
J Clin Oncol; 2011 Jun; 29(16):2171-7. PubMed ID: 21502557
[TBL] [Abstract][Full Text] [Related]
9. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.
Plimack ER; Hoffman-Censits JH; Viterbo R; Trabulsi EJ; Ross EA; Greenberg RE; Chen DY; Lallas CD; Wong YN; Lin J; Kutikov A; Dotan E; Brennan TA; Palma N; Dulaimi E; Mehrazin R; Boorjian SA; Kelly WK; Uzzo RG; Hudes GR
J Clin Oncol; 2014 Jun; 32(18):1895-901. PubMed ID: 24821881
[TBL] [Abstract][Full Text] [Related]
10. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
Ennis RD; Petrylak DP; Singh P; Bagiella E; O'Toole KM; Benson MC; Olsson CA
J Urol; 2000 May; 163(5):1413-8. PubMed ID: 10751847
[TBL] [Abstract][Full Text] [Related]
11. [Neoadjuvant chemotherapy in muscle-invasive bladder cancer].
Miyanaga N; Akaza H
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1745-9. PubMed ID: 18030008
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy is not (yet) standard treatment for muscle-invasive bladder cancer.
Sternberg CN; Parmar MK
J Clin Oncol; 2001 Sep; 19(18 Suppl):21S-26S. PubMed ID: 11560967
[No Abstract] [Full Text] [Related]
13. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists.
Lancet; 1999 Aug; 354(9178):533-40. PubMed ID: 10470696
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant gemcitabine plus cisplatin for muscle-invasive bladder cancer.
Kaneko G; Kikuchi E; Matsumoto K; Obata J; Nakamura S; Miyajima A; Oya M
Jpn J Clin Oncol; 2011 Jul; 41(7):908-14. PubMed ID: 21665907
[TBL] [Abstract][Full Text] [Related]
15. [Neoadjuvant chemotherapy for invasive bladder cancer].
Kageyama Y; Kihara K
Gan To Kagaku Ryoho; 2001 Nov; 28(12):1838-44. PubMed ID: 11729476
[TBL] [Abstract][Full Text] [Related]
16. The current status of perioperative chemotherapy for invasive bladder cancer: a multiinstitutional retrospective study in Japan.
Matsui Y; Nishiyama H; Watanabe J; Teramukai S; Ono Y; Ohshima S; Fujimoto K; Hirao Y; Fukushima M; Ogawa O
Int J Clin Oncol; 2005 Apr; 10(2):133-8. PubMed ID: 15864700
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.
Vetterlein MW; Wankowicz SAM; Seisen T; Lander R; Löppenberg B; Chun FK; Menon M; Sun M; Barletta JA; Choueiri TK; Bellmunt J; Trinh QD; Preston MA
Cancer; 2017 Nov; 123(22):4346-4355. PubMed ID: 28743155
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R
BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762
[TBL] [Abstract][Full Text] [Related]
19. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC.
Millikan R; Dinney C; Swanson D; Sweeney P; Ro JY; Smith TL; Williams D; Logothetis C
J Clin Oncol; 2001 Oct; 19(20):4005-13. PubMed ID: 11600601
[TBL] [Abstract][Full Text] [Related]
20. Retrospective analysis of the efficacy of two cycles of M-VAC neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive bladder cancer.
Kitagawa Y; Izumi K; Miwa S; Kadono Y; Konaka H; Mizokami A; Namiki M
Anticancer Res; 2013 Oct; 33(10):4497-503. PubMed ID: 24123021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
